LONDON, June 16, 2008-The European Medicines Agency (EMEA) has been formally notified by Novartis Vaccines and Diagnostics S.r.l. of its decision to withdraw the application for a centralised marketing authorisation for the pre-pandemic vaccine Aflunov (A/VietNam/1194/2004 (H5N1) virus surface inactivated antigen).
Aflunov was expected to be used for active pre-pandemic immunisation against H5N1 subtype of the influenza A virus.
The details can be read here.
No comments:
Post a Comment